



Altimune to Present Pemvidutide Clinical Data at Upcoming NASH-TAG Conference January 8, 2022

January 3, 2022

GAITHERSBURG, Md., Jan. 03, 2022 (GLOBE NEWSWIRE) -- Altimune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that Dr. Scott Harris, Chief Medical Officer at Altimune, will give an oral and a poster presentation on pemvidutide, the Company's novel, investigational GLP-1/Glucagon dual receptor agonist under development for the treatment of obesity and non-alcoholic steatohepatitis (NASH), the most severe form of non-alcoholic fatty liver disease (NAFLD). The presentations will take place at the NASH-TAG Conference, which is being held January 6-8, 2022, in Park City, Utah. Details for the oral presentation are as follows:

Title:	A placebo-controlled, double-blind, first-in-human study of Pemvidutide (ALT-801), a novel GLP-1/glucagon dual receptor agonist for the treatment of NASH and obesity
Presenter:	Scott Harris, M.D., Chief Medical Officer, Altimune, Inc.
Date/Time:	Saturday, January 8, 2022 at 8:10 am Mountain Time

A copy of Dr. Harris' presentation and poster will be accessible on the [Events](#) section of the Altimune website.

About Altimune

Altimune is a clinical stage biopharmaceutical company focused on developing treatments for obesity and liver diseases. Our pipeline includes next generation peptide therapeutics for obesity, NASH (pemvidutide), and chronic hepatitis B (HepTcell™). For more information, please visit www.altimmune.com.

Follow @Altimune, Inc. on [LinkedIn](#)

Follow @AltimuneInc on [Twitter](#)

Investor & Media Contacts:

Richard Eisenstadt
Chief Financial Officer
Phone: 240-654-1450
reisenstadt@altimmune.com



Source: Altimune, Inc